Q2 2016 13F Holders as of 6/30/2016
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
51.2M
-
Shares change
-
-3.67M
-
Total reported value, excl. options
-
$145M
-
Value change
-
-$10.4M
-
Put/Call ratio
-
0.33
-
Number of buys
-
40
-
Number of sells
-
-48
-
Price
-
$2.84
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q2 2016
114 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q2 2016.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.2M shares
of 210M outstanding shares and own 24.42% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (15M shares), VHCP Management II, LLC (5.72M shares), VANGUARD GROUP INC (3.53M shares), D. E. Shaw & Co., Inc. (3.43M shares), RA CAPITAL MANAGEMENT, LLC (2.99M shares), BlackRock Fund Advisors (2.85M shares), RTW INVESTMENTS, LLC (2.24M shares), BlackRock Institutional Trust Company, N.A. (1.85M shares), Ghost Tree Capital, LLC (1.7M shares), and JENNISON ASSOCIATES LLC (1.36M shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.